Learning Objectives

What You'll Learn Today

By the end of this session, you will be able to:

Section 1

Precedent Transactions — Overview

Understanding M&A-based valuation through historical deal data

💭
Think About It

Why might an acquirer pay significantly more for a company than what its shares currently trade at in the open market?

Take 30 seconds to think about the concept of "control" and "synergies" before we discuss as a class

📖 What Are Precedent Transactions?

🏠 Start With an Analogy

Imagine you own a 3BHK apartment in a housing society. You want to know what it's worth. You could check what similar apartments are currently listed for (that's like trading comps from Session 12). But a smarter approach is to look at what similar apartments actually sold for in recent months — because listed prices and sold prices can be very different. The actual transaction prices tell you what real buyers were willing to pay, not what sellers are hoping to get.

Precedent Transaction Analysis works the same way for companies. Instead of looking at today's stock price (which is just what a small slice of the company trades at), you look at the actual prices paid in recent M&A deals for entire companies in the same industry. These real deal prices tell you what acquirers — after months of due diligence, negotiation, and strategic analysis — were genuinely willing to pay to take over a business.

🧩 The Core Logic — Three Simple Steps

  1. Find similar deals: Look at recent M&A transactions where companies in the same industry were acquired — same sector, similar size, same country.
  2. Extract the "price tag" multiple: For each deal, calculate how much the acquirer paid relative to the target's earnings (e.g., "they paid 9× the target's EBITDA"). This is the transaction multiple.
  3. Apply it to your company: Multiply your target company's earnings by the median multiple from those deals. The result is an estimate of what your company might be worth if acquired today.

🔢 A Quick Numerical Example

Suppose 5 Indian pharma companies were acquired in the last 3 years. In each deal, the acquirer paid roughly 9 times the target's EBITDA (the median was 9.0×).

Now you're valuing MedCore Therapeutics, which has:

  • LTM EBITDA = ₹920 Cr
  • Net Debt = ₹650 Cr
  • Shares Outstanding = 20.0 Cr
Step 1: Implied Enterprise Value = ₹920 Cr × 9.0x = ₹8,280 Cr
Step 2: Implied Equity Value = ₹8,280 Cr − ₹650 Cr (net debt) = ₹7,630 Cr
Step 3: Implied Share Price = ₹7,630 Cr ÷ 20.0 Cr shares = ₹381.50/share

That's it — you've just valued a company using precedent transactions. Everything else in this session is about doing this more rigorously.

📘 The Formal Definition

Precedent Transaction Analysis (also called "M&A Comps" or "Transaction Comps") is a relative valuation methodology that estimates the value of a target company by examining the valuation multiples paid in comparable, completed M&A transactions. Unlike trading comparables (Session 12), which use current market prices reflecting minority (non-control) value, precedent transactions capture the prices actually paid by acquirers to gain control of entire businesses — making them especially relevant for M&A, takeover, and LBO scenarios.

Implied Value = Target's Financial Metric × Median Transaction Multiple
e.g., Implied EV = Target's EBITDA × Median EV/EBITDA from precedent deals
💡 Key Insight — The Control Premium

When you buy one share on the stock exchange, you're a passive investor — you have no say in how the company is run. But when an acquirer buys the entire company, they gain control: the power to change management, redirect strategy, merge operations, and extract synergies. That control is valuable — so acquirers pay a control premium (typically 15–35% in India) above the market price. This means precedent transaction multiples are almost always higher than trading multiples for the same peer group — and that's exactly what makes them useful for valuing potential acquisition targets.

🎯 When Do Bankers Use This Method?

Investment bankers use multiple methods to estimate the value of a company being considered for an acquisition or takeover. Typically, they will run three different approaches in parallel: discounted cash flow (DCF), trading comparables (market value), and precedent transactions (deal value). These three methodologies are used to arrive at a more accurate valuation estimate than by relying on any single methodology.
The first two approaches, DCF and trading comparables, are commonly used in the business world. DCF estimates a company's intrinsic value based on its future cash flows, while trading comparables estimate its market value based on the prices of similar companies traded on public exchanges.
However, precedent transactions play a specific and important role in this process. Precedent transactions are those in which real acquirers have actually paid for companies that are similar to the target company being valued. This approach allows investment bankers to answer the question "What have real acquirers actually paid for companies like this?" — a question that neither DCF nor trading comps can answer directly.
By presenting all three approaches side-by-side in a "football field" chart, investment bankers can provide a more comprehensive and accurate estimate of the target company's value, taking into account different scenarios and uncertainties.

✅ Best Used When... ⚠️ Less Useful When...
Valuing a company for a potential acquisition or takeover No comparable M&A transactions exist in the sector
Determining a fair offer price — "What should we bid?" All available deals are too old (>5 years) or in different geographies
Defending against a takeover — "Is the offer fair to our shareholders?" The target is in a unique niche with no real peers
Preparing a fairness opinion for the target's board of directors You need a going-concern value (not a takeover value)
Pricing an LBO / take-private transaction for a PE firm The sector is undergoing a major disruption (past deals may not reflect new reality)
Building a "football field" valuation range alongside DCF and trading comps Deal multiples are heavily distorted by one or two outlier transactions
🏦 Real-World Example — Fairness Opinion

When Sun Pharmaceutical acquired Alembic Pharma's API unit, the investment banker's fairness opinion needed to justify the 18.5% control premium to Alembic's board. The banker cited precedent transaction multiples ranging from 8.0x to 11.8x EV/EBITDA in the Indian pharma sector — showing that the implied 9.0x multiple fell squarely within the observed range. This is how precedent transactions directly influence real deal pricing and board approval decisions.

⚖️ Trading Comps vs. Transaction Comps

📊 Trading Comps (Session 12)

  • ✅ Based on current market prices
  • ✅ Reflects minority (non-control) value
  • ✅ Data is readily available and timely
  • ✅ Easily updated in real-time
  • ⚠️ May not reflect M&A premium
  • ⚠️ Subject to market sentiment and volatility

🏦 Transaction Comps (This Session)

  • ✅ Based on actual prices paid in M&A
  • ✅ Includes control premium
  • ✅ Captures synergy expectations
  • ✅ Better for M&A / takeover valuations
  • ⚠️ Historical data may be outdated
  • ⚠️ Fewer comparable transactions available

📋 The 5-Step Process

1 Select Universe
→
2 Source Data
→
3 Calculate Multiples
→
4 Analyze Premiums
→
5 Value Target

Identify completed M&A transactions in the same sector as your target. Screening criteria include:

  • Sector match: Same or adjacent industry (e.g., Indian Pharma)
  • Size proximity: Deal value within a reasonable range (±50-70%)
  • Geography: Same country/region for regulatory comparability
  • Recency: Typically last 3-5 years; more recent = more relevant
  • Deal type: Comparable transaction structures (100% acquisition, asset purchase, merger)
📌Indian Pharma Case

For our session, we analyze 10 completed M&A transactions in the Indian pharmaceutical sector (2022-2024), covering deal sizes from ₹3,600 Cr to ₹12,400 Cr.

For each precedent transaction, gather the following data points:

Data Category Specific Items Source
Deal Data Announcement date, closing date, deal type, consideration mix (cash/stock) BSE/NSE filings, SEBI announcements
Transaction Value Equity value (offer price × shares), Implied Enterprise Value (EV) Press releases, Tender offer documents
Target Financials LTM revenue, EBITDA, net income at announcement Annual reports, Capital IQ, BSE filings
Share Price Unaffected share price (pre-deal), Offer price per share NSE/BSE historical data

Compute the same multiples used in trading comps, but using the deal-implied values:

EV / EBITDA = Implied Enterprise Value ÷ Target LTM EBITDA
EV / Revenue = Implied Enterprise Value ÷ Target LTM Revenue
P / E = Offer Price Per Share ÷ Target LTM EPS
Control Premium = (Offer Price − Unaffected Price) ÷ Unaffected Price × 100

Compute summary statistics for the transaction set:

  • Mean — Average of all multiples (sensitive to outliers)
  • Median — Middle value (preferred — robust to outliers)
  • Min / Max — Range of observed multiples
  • 25th / 75th Percentile — For framing a valuation range
⚠️Watch Out

A single outlier deal can distort the mean. Always report the median alongside the mean. If one deal has an EV/EBITDA of 25x while others cluster around 9x, investigate whether it involves unique strategic rationale (e.g., patent portfolio, market entry).

Apply the median/mean transaction multiples to the target's financials:

Implied EV of Target = Target LTM EBITDA × Median EV/EBITDA (from precedents)
Implied Equity Value = Implied EV − Net Debt
Implied Share Price = Implied Equity Value ÷ Shares Outstanding

Compare this to the target's current market price to assess whether the company is fairly valued, undervalued, or overvalued relative to what acquirers have historically paid.

Section 2

Indian Pharma M&A Transaction Data

10 recent deals forming our precedent transaction universe

📊 Complete Transaction Data Table

All values in ₹ Crores unless otherwise stated

📖 How to Read This Table — Understanding Each Column

The table below has 11 columns. They are not random — they follow a logical calculation flow. Think of them in three groups:

Group 1 Deal Identification — Who, Whom, When, How
ColumnWhat It MeansExample (Row 1)
Target CompanyThe company (or division) that was acquired. This is the company whose valuation we study.Cipla Health (Consumer)
AcquirerThe company (or PE firm) that bought the target. Note whether it's a strategic buyer (another pharma company) or a financial buyer (PE firm like KKR).Dr. Reddy's Labs
AnnouncedWhen the deal was publicly announced. More recent deals are more relevant for valuation.Jan 2024
Deal TypeHow the deal was structured — 100% acquisition, asset purchase, merger, strategic stake, etc. This affects comparability.100% Acquisition
Group 2 Deal Sizing — The Raw Numbers (How Much Was Paid & What Was Earned)
ColumnWhat It MeansExample (Row 1)
Txn Value (₹ Cr)The Transaction Equity Value — total amount paid for the target's shares. Calculated as: Offer Price per Share × Total Shares Outstanding. This is what the acquirer paid the shareholders.₹8,500 Cr
Implied EV (₹ Cr)The Implied Enterprise Value — total value of the entire business, including debt. Calculated as: Txn Value + Net Debt. EV is always ≥ Txn Value because it adds the target's debt obligations.₹9,200 Cr
(₹8,500 + ₹700 debt)
LTM EBITDA (₹ Cr)The target's Last Twelve Months EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) at the time of the deal. This is the target's operating profit — the "base" to which we apply multiples.₹780 Cr
Group 3 Valuation Multiples — The Calculated Ratios (The "Price Tags")
ColumnWhat It MeansExample (Row 1)
EV/EBITDA= Implied EV ÷ LTM EBITDA → "The acquirer paid 11.8× the target's EBITDA." This is the most important multiple — it tells you how many years of EBITDA the acquirer paid for. Higher = more expensive.11.8x
(₹9,200 ÷ ₹780)
EV/Revenue= Implied EV ÷ LTM Revenue → "The acquirer paid 2.9× the target's annual revenue." Useful when EBITDA is volatile or negative.2.9x
P/E= Offer Price per Share ÷ EPS → Price-to-Earnings ratio at the deal price. Popular in India but affected by debt structure and tax rates.20.2x
Premium= (Offer Price − Unaffected Price) ÷ Unaffected Price × 100 → How much extra the acquirer paid above the target's pre-deal market price. This is the control premium. A 30.8% premium means the acquirer paid ~31% more than what the market valued the company at before the deal news.30.8%
(₹680 offer − ₹520 unaffected) ÷ ₹520

The Calculation Flow — How Columns Connect:

Txn Value (₹8,500) + Net Debt (₹700) → Implied EV (₹9,200) → ÷ EBITDA (₹780) → EV/EBITDA = 11.8x

The same Implied EV is divided by Revenue to get EV/Revenue, and Offer Price is divided by EPS to get P/E. The Premium is calculated independently from share prices.

Target Company Acquirer Announced Deal Type Txn Value (₹ Cr) Implied EV (₹ Cr) LTM EBITDA (₹ Cr) EV/EBITDA EV/Revenue P/E Premium
Cipla Health (Consumer) Dr. Reddy's Labs Jan 2024 100% Acquisition 8,500 9,200 780 11.8x 2.9x 20.2x 30.8%
Mankind Pharma Block Bharat Biotech Aug 2023 Strategic Stake 12,400 13,500 1,680 8.0x 2.4x 13.5x 17.0%
Alembic Pharma (API) Sun Pharmaceutical Jun 2023 Asset Purchase 4,800 5,200 580 9.0x 2.5x 15.5x 18.5%
Lupin (Brazil Sub.) Zydus Lifesciences Nov 2023 Cross-border 6,200 7,100 750 9.5x 2.4x 19.9x 17.1%
Gland Pharma Fosun Pharma (China) Oct 2022 100% Acquisition 7,800 8,900 920 9.7x 2.6x 15.3x 16.5%
Biological E. (Generics) Serum Institute Apr 2023 Merger 5,400 6,100 680 9.0x 2.3x 15.0x 14.0%
J.B. Chemicals KKR (PE) Jul 2022 Take-Private 7,200 8,000 820 9.8x 2.9x 15.3x 12.4%
Marksons Pharma Torrent Pharma Feb 2024 100% Acquisition 3,600 4,100 490 8.4x 2.3x 12.9x 16.1%
Strides Shasun (OSD) Mankind Pharma Dec 2023 Divestiture 4,100 4,600 560 8.2x 2.1x 13.2x 14.0%
Intas Pharma (Sterile) Alkem Labs Sep 2023 Asset Purchase 5,500 6,300 720 8.8x 2.4x 13.9x 17.0%
Summary — Median - - - 5,950 6,700 735 9.0x 2.4x 15.1x 16.3%
📝 Worked Example 1

Calculating Implied Enterprise Value & Transaction Multiples

Deal: Dr. Reddy's acquires Cipla Health (Consumer Division)

Given Data:
• Transaction Equity Value (Offer Price × Shares) = ₹8,500 Cr
• Target Net Debt = ₹700 Cr
• Target LTM EBITDA = ₹780 Cr
• Target LTM Revenue = ₹3,200 Cr

Questions: (a) What is the Implied Enterprise Value? (b) Calculate EV/EBITDA and EV/Revenue multiples.
1
Calculate Implied Enterprise Value
Implied EV = Equity Value + Net Debt
Implied EV = ₹8,500 Cr + ₹700 Cr
Implied EV = ₹9,200 Cr
2
Calculate EV/EBITDA Multiple
EV/EBITDA = Implied EV ÷ Target LTM EBITDA
EV/EBITDA = ₹9,200 Cr ÷ ₹780 Cr
EV/EBITDA = 11.79x ≈ 11.8x
3
Calculate EV/Revenue Multiple
EV/Revenue = Implied EV ÷ Target LTM Revenue
EV/Revenue = ₹9,200 Cr ÷ ₹3,200 Cr
EV/Revenue = 2.875x ≈ 2.9x
Implied EV = ₹9,200 Cr | EV/EBITDA = 11.8x | EV/Revenue = 2.9x
Section 3

Transaction Multiples — Deep Dive

Understanding EV/EBITDA, EV/Revenue, and P/E in an M&A context

📋 Transaction Multiple Selection Guide

Multiple Formula When to Use Key Consideration
EV/EBITDA Implied EV ÷ LTM EBITDA Most widely used; capital-structure neutral Ensure EBITDA is normalized (adjust for one-time items)
EV/Revenue Implied EV ÷ LTM Revenue When EBITDA is negative or highly variable Ignores profitability — useful only when margins are comparable
P/E Offer Price ÷ LTM EPS For equity-level valuation; popular in India Distorted by capital structure, tax, and non-recurring items
📝 Worked Example 2

Valuing a Hypothetical Target Using Precedent Multiples

Scenario: You are valuing "PharmaVista Ltd.", a mid-cap Indian specialty pharma company. You have the following data:

PharmaVista Financials:
• LTM EBITDA = ₹1,200 Cr
• LTM Revenue = ₹4,800 Cr
• LTM Net Income = ₹660 Cr
• Net Debt = ₹900 Cr
• Shares Outstanding = 18.0 Cr

Precedent Transaction Medians (from our Pharma universe):
• Median EV/EBITDA = 9.0x | Median EV/Revenue = 2.4x | Median P/E = 15.1x

Questions: (a) Calculate implied EV, equity value, and share price using each multiple. (b) Which multiple gives the most reliable result?
1
Method A: EV/EBITDA Multiple
Implied EV = ₹1,200 Cr × 9.0x = ₹10,800 Cr
Implied Equity Value = ₹10,800 Cr − ₹900 Cr = ₹9,900 Cr
Implied Share Price = ₹9,900 Cr ÷ 18.0 Cr shares = ₹550/share
2
Method B: EV/Revenue Multiple
Implied EV = ₹4,800 Cr × 2.4x = ₹11,520 Cr
Implied Equity Value = ₹11,520 Cr − ₹900 Cr = ₹10,620 Cr
Implied Share Price = ₹10,620 Cr ÷ 18.0 Cr shares = ₹590/share
3
Method C: P/E Multiple
LTM EPS = ₹660 Cr ÷ 18.0 Cr = ₹36.67/share
Implied Share Price = ₹36.67 × 15.1x = ₹553.7/share
Implied Equity Value = ₹553.7 × 18.0 Cr = ₹9,967 Cr
Implied EV = ₹9,967 Cr + ₹900 Cr = ₹10,867 Cr
4
Summary & Cross-Check
Method A (EV/EBITDA): Implied Price = ₹550/share
Method B (EV/Revenue): Implied Price = ₹590/share
Method C (P/E): Implied Price = ₹554/share
Valuation Range: ₹550 – ₹590/share | EV/EBITDA is most reliable for pharma (capital-intensive, consistent EBITDA definition)
⚠️ Understanding Synergy Assumptions

Transaction multiples embed the acquirer's expectation of synergies. If an acquirer pays a 30% premium, they likely expect cost savings (overlapping operations, procurement efficiencies) or revenue synergies (cross-selling, expanded geographic reach) exceeding that premium. When applying precedent multiples to a target, consider whether the same level of synergies would be available to a potential acquirer of YOUR target.

Section 4

Control Premiums Analysis

Quantifying the value of control in M&A transactions

📖 What Is a Control Premium?

🚌 Start With an Analogy

Imagine you're a passenger on a bus. You paid for your ticket, you get a seat, and you'll reach the destination — but you have zero say in which route the bus takes, who the driver is, or when it stops. That's like being a minority shareholder — you own a piece of the company, but you don't control it.

Now imagine you buy the entire bus. You can fire the driver, change the route, paint it a new color, remove seats to add cargo space, or even merge it with another bus company. That's what happens when an acquirer buys a controlling stake (>50%) in a company. They gain the power to make all the decisions — and that power is valuable. The extra amount they pay above the market price to get that power is called the control premium.

🧩 Plain English Explanation

When you buy shares on the stock exchange, you pay the market price. This price reflects what passive investors think the company is worth — based on publicly available information, without any power to change how the company operates.

But when an acquirer wants to buy the entire company, they must pay more than the market price. Why? Because:

  • The target's board won't accept the current market price — shareholders need an incentive to sell
  • Controlling the company unlocks value that passive shareholders can't access — the acquirer can restructure, merge, cut costs, or redirect strategy
  • There may be competing bidders — driving the price up through an auction process

🔑 What Does "Control" Actually Give the Acquirer?

When an acquirer gains control (>50% voting power), they can:

Power of ControlWhat It MeansFinancial Impact
Replace managementFire the CEO, change the board, bring in a new leadership teamBetter operational execution → higher profits
Change strategyEnter new markets, exit unprofitable segments, launch new productsRevenue growth or margin improvement
Merge operationsCombine with existing businesses — shared warehouses, procurement, distributionCost synergies (often 10–20% of combined OpEx)
Sell assetsDivest non-core divisions, sell real estate, monetize patentsImmediate cash inflow to fund the acquisition
Access cash flowsRedirect dividends, inter-company loans, or cash reservesDebt repayment or reinvestment opportunities

🔢 A Concrete Example — Alembic Pharma Deal

When Sun Pharmaceutical acquired Alembic Pharma's API unit, here's what happened to the share price:

Unaffected Price
₹270
What market thought it was worth
→
Offer Price
₹320
What Sun Pharma actually paid
Control Premium
+₹50
= 18.5% extra

What does this mean for a shareholder? If you held 100 shares of Alembic before the deal, your shares were worth ₹27,000 at market price. Sun Pharma offered you ₹32,000 for those same 100 shares — an extra ₹5,000 because they wanted control of the company to integrate it with their own API manufacturing.

📏 What Is the "Unaffected Share Price"?

The unaffected share price is the target's stock price before any news, rumors, or speculation about the deal affected the price. We need this "clean" price to measure the true premium.

Why does this matter? Because once rumors of a takeover leak, the share price typically jumps 5–10% on speculation alone. If we used the post-rumor price, the calculated premium would be too low.

Time WindowHow It's CalculatedWhen to Use
1-Day VWAPVolume-weighted average price on the day before announcementMost common — used when no pre-leakage
7-Day VWAPAverage of 7 trading days before announcementSmooths out daily volatility
30-Day VWAPAverage of 30 trading days before announcementGold standard — removes speculation effects; used in fairness opinions

📘 Formal Definition & Formula

A control premium is the additional amount an acquirer pays above the target's unaffected market price to obtain a controlling interest (typically >50% voting power). In India, open offers under SEBI Takeover Regulations typically require acquiring at least 26% from public shareholders at the offer price.

Control Premium = (Offer Price − Unaffected Price) ÷ Unaffected Price × 100%
e.g., (₹320 − ₹270) ÷ ₹270 × 100% = 18.5%
💡 Indian Market Context

Control premiums in India typically range from 15% to 35%. The median premium in our pharma dataset is 16.3%. Premiums tend to be higher for strategic acquisitions vs. financial sponsor (PE) purchases, and for unique assets (patents, distribution networks, regulatory approvals).

📊 Control Premium Breakdown — Pharma Deals

Target Acquirer Type Unaffected Price (₹) Offer Price (₹) Control Premium Key Driver
Cipla Health (Consumer) Strategic 520 680 30.8% OTC brand portfolio + distribution
Alembic Pharma (API) Strategic 270 320 18.5% API manufacturing capacity
J.B. Chemicals PE (Financial) 413 464 12.4% Take-private at moderate premium
Biological E. (Generics) Strategic 215 245 14.0% Vaccine production capability
Gland Pharma Cross-border Strategic 418 487 16.5% Injectable sterile expertise
📝 Worked Example 3

Control Premium Calculation & Analysis

Deal: Sun Pharmaceutical acquires Alembic Pharma (API Unit)

• Unaffected Share Price (30-day VWAP before announcement): ₹270
• Offer Price Per Share: ₹320
• Shares Outstanding: 15.0 Cr
• Target LTM Net Income: ₹310 Cr

Questions: (a) Calculate the control premium. (b) What is the P/E multiple on a standalone basis vs. including the premium? (c) Why might Sun Pharma be willing to pay this premium?
1
Calculate Control Premium
Control Premium = (Offer Price − Unaffected Price) ÷ Unaffected Price × 100
Control Premium = (₹320 − ₹270) ÷ ₹270 × 100
Control Premium = ₹50 ÷ ₹270 × 100 = 18.52% ≈ 18.5%
2
Standalone P/E vs. Transaction P/E
LTM EPS = ₹310 Cr ÷ 15.0 Cr shares = ₹20.67/share

Standalone P/E (at unaffected price) = ₹270 ÷ ₹20.67 = 13.1x
Transaction P/E (at offer price) = ₹320 ÷ ₹20.67 = 15.5x
3
Interpretation
The premium of 18.5% reflects Sun Pharma's expectation that Alembic's API
manufacturing capacity will generate synergies exceeding ₹600 Cr (estimated)
through vertical integration, procurement savings, and capacity utilization.
Control Premium = 18.5% | The premium is justified by strategic API integration synergies

🔄 Deal Structure & Its Impact on Valuation

The form of consideration (cash vs. stock vs. mix) affects the effective premium received by target shareholders:

Consideration Type Description Impact on Premium Example from Dataset
100% Cash Certain value; target shareholders receive fixed amount Lower perceived risk → may accept lower premium Cipla Health, Alembic, Marksons, Strides
100% Stock Target shareholders receive acquirer shares; subject to market risk Higher risk → target demands higher premium None in our dataset (rare in India)
Mixed (Cash + Stock) Combination; balances certainty with upside potential Moderate premium; both parties share risk Mankind Block (75/25), Lupin Brazil (80/20)
Excel Lab

Hands-On Practice Exercises

Build your own Precedent Transaction Analysis in Excel

📥 Download Practice Files

Download these CSV files and open them in Excel to complete the exercises below. The practice file has key fields left blank for you to calculate. The premium analysis file contains supplementary data.

📊
lecture-13-precedent-transactions-practice.csv
Practice Template (blanks to fill)
⬇
📈
lecture-13-premium-analysis.csv
Premium & Synergy Data
⬇
📋
lecture-13-precedent-transactions.csv
Complete Reference Data
⬇

🏋️ Exercise 1: Calculate Implied Enterprise Value & Transaction Multiples

Open the lecture-13-precedent-transactions-practice.csv file in Excel. The "Implied EV", "EV/Revenue", "EV/EBITDA", and "P/E" columns are left blank.

  1. Step A: In Column B (Implied EV), calculate: = [Transaction Value] + [Target Net Debt]
  2. Step B: In Column O (EV/Revenue), calculate: = [Implied EV] / [Target LTM Revenue] and format as "0.0x"
  3. Step C: In Column P (EV/EBITDA), calculate: = [Implied EV] / [Target LTM EBITDA] and format as "0.0x"
  4. Step D: In Column Q (P/E), calculate: = [Offer Price Per Share] / ([Target LTM Net Income] / [Shares Outstanding]) and format as "0.0x"
  5. Step E: At the bottom of each multiple column, compute the MEDIAN using =MEDIAN(range)

✅ Completed Transaction Multiples

Target Txn Value (₹ Cr) + Net Debt = Implied EV (₹ Cr) ÷ Revenue EV/Revenue ÷ EBITDA EV/EBITDA P/E
Cipla Health 8,500+ 7009,200÷ 3,2002.9x÷ 78011.8x20.2x
Mankind Block 12,400+ 1,10013,500÷ 5,6002.4x÷ 1,6808.0x13.5x
Alembic (API) 4,800+ 4005,200÷ 2,1002.5x÷ 5809.0x15.5x
Lupin (Brazil) 6,200+ 9007,100÷ 2,9002.4x÷ 7509.5x19.9x
Gland Pharma 7,800+ 1,1008,900÷ 3,4002.6x÷ 9209.7x15.3x
Biological E. 5,400+ 7006,100÷ 2,6002.3x÷ 6809.0x15.0x
J.B. Chemicals 7,200+ 8008,000÷ 2,8002.9x÷ 8209.8x15.3x
Marksons 3,600+ 5004,100÷ 1,8002.3x÷ 4908.4x12.9x
Strides (OSD) 4,100+ 5004,600÷ 2,2002.1x÷ 5608.2x13.2x
Intas (Sterile) 5,500+ 8006,300÷ 2,6002.4x÷ 7208.8x13.9x
MEDIAN ---- 2.4x- 9.0x 15.1x
Excel Formulas Used:
Implied EV: =H2+L2 (Transaction Value + Net Debt)
EV/Revenue: =I2/D2 → format as "0.0"x"
EV/EBITDA: =I2/E2 → format as "0.0"x"
P/E: =N2/(F2/M2) → Offer Price ÷ (Net Income ÷ Shares Outstanding)
MEDIAN: =MEDIAN(P2:P11)

🏋️ Exercise 2: Value a Target Company Using Precedent Multiples

A new Indian pharma company, "MedCore Therapeutics", is being considered for acquisition. Use the precedent transaction multiples you calculated in Exercise 1 to value MedCore.

MedCore Therapeutics — Financial Data:

  • LTM Revenue: ₹3,800 Cr
  • LTM EBITDA: ₹920 Cr
  • LTM Net Income: ₹510 Cr
  • Net Debt: ₹650 Cr
  • Shares Outstanding: 20.0 Cr
  • Current Market Price: ₹310/share
  1. Task A: Using the median EV/EBITDA (9.0x), calculate Implied EV, Equity Value, and Implied Share Price
  2. Task B: Using the median EV/Revenue (2.4x), calculate Implied EV, Equity Value, and Implied Share Price
  3. Task C: Using the median P/E (15.1x), calculate Implied Share Price, Equity Value, and Implied EV
  4. Task D: Compare the implied share prices to MedCore's current market price (₹310). Is MedCore undervalued or overvalued?
  5. Task E: If a potential acquirer expects synergies of ₹400 Cr, what is the maximum EV/EBITDA multiple they could justify paying?
A
EV/EBITDA Method (Median = 9.0x)
Implied EV = ₹920 Cr × 9.0x = ₹8,280 Cr
Implied Equity Value = ₹8,280 Cr − ₹650 Cr = ₹7,630 Cr
Implied Share Price = ₹7,630 Cr ÷ 20.0 Cr = ₹381.50/share
B
EV/Revenue Method (Median = 2.4x)
Implied EV = ₹3,800 Cr × 2.4x = ₹9,120 Cr
Implied Equity Value = ₹9,120 Cr − ₹650 Cr = ₹8,470 Cr
Implied Share Price = ₹8,470 Cr ÷ 20.0 Cr = ₹423.50/share
C
P/E Method (Median = 15.1x)
LTM EPS = ₹510 Cr ÷ 20.0 Cr = ₹25.50/share
Implied Share Price = ₹25.50 × 15.1x = ₹385.05/share
Implied Equity Value = ₹385.05 × 20.0 Cr = ₹7,701 Cr
Implied EV = ₹7,701 Cr + ₹650 Cr = ₹8,351 Cr
D
Comparison to Market Price (₹310)
EV/EBITDA Implied Price: ₹381.50 (premium to market: 23.1%)
EV/Revenue Implied Price: ₹423.50 (premium to market: 36.6%)
P/E Implied Price: ₹385.05 (premium to market: 24.2%)
MedCore appears UNDervalued at ₹310/share. Precedent transactions suggest a value range of ₹382-₹424/share, implying the market is not pricing in a potential acquisition premium.
E
Synergy-Adjusted Maximum Multiple
Without synergies, max EV = ₹8,280 Cr (at 9.0x EBITDA)
With ₹400 Cr synergies, combined EBITDA = ₹920 + ₹400 = ₹1,320 Cr
At same implied EV of ₹8,280: Multiple = ₹8,280 ÷ ₹1,320 = 6.3x

Alternatively: Max EV an acquirer would pay = (₹920 + ₹400) × 9.0x = ₹11,880 Cr
Max EV/EBITDA (on standalone EBITDA) = ₹11,880 ÷ ₹920 = 12.9x
With ₹400 Cr synergies, the acquirer could justify paying up to 12.9x standalone EBITDA (vs. median 9.0x without synergies)

🏋️ Exercise 3: Control Premium Analysis

Open the lecture-13-premium-analysis.csv file. Complete the following:

  1. Task A: Verify the Market Cap Pre-Deal column: = [Unaffected Share Price] × [Shares Outstanding]
  2. Task B: Verify the Transaction Equity Value column: = [Offer Price] × [Shares Outstanding]
  3. Task C: Recalculate the Control Premium %: = ([Offer Price] − [Unaffected Price]) / [Unaffected Price]
  4. Task D: Calculate the Synergy-to-Premium Ratio: = [Synergies Estimated] / ([Transaction Equity Value] − [Market Cap Pre-Deal])
  5. Task E: What patterns do you notice? Are higher premiums associated with strategic or financial acquirers?
D
Synergy-to-Premium Ratio
Premium Paid = Transaction Equity Value − Market Cap Pre-Deal

Cipla Health: Premium = ₹8,500 − ₹6,500 = ₹2,000 Cr → Ratio = ₹1,200/₹2,000 = 0.60x
Mankind Block: Premium = ₹12,400 − ₹10,600 = ₹1,800 Cr → Ratio = ₹1,800/₹1,800 = 1.00x
Alembic (API): Premium = ₹4,800 − ₹4,050 = ₹750 Cr → Ratio = ₹600/₹750 = 0.80x
Lupin (Brazil): Premium = ₹6,200 − ₹5,296 = ₹904 Cr → Ratio = ₹950/₹904 = 1.05x
Gland Pharma: Premium = ₹7,792 − ₹6,688 = ₹1,104 Cr → Ratio = ₹1,100/₹1,104 = 1.00x
Biological E.: Premium = ₹5,390 − ₹4,730 = ₹660 Cr → Ratio = ₹700/₹660 = 1.06x
J.B. Chemicals: Premium = ₹7,192 − ₹6,402 = ₹790 Cr → Ratio = ₹900/₹790 = 1.14x
Marksons: Premium = ₹3,600 − ₹3,100 = ₹500 Cr → Ratio = ₹500/₹500 = 1.00x
Strides (OSD): Premium = ₹4,104 − ₹3,600 = ₹504 Cr → Ratio = ₹650/₹504 = 1.29x
Intas (Sterile): Premium = ₹5,502 − ₹4,704 = ₹798 Cr → Ratio = ₹800/₹798 = 1.00x
E
Key Observations
1. Strategic acquirers (Dr. Reddy's, Sun Pharma) tend to pay higher premiums (18-31%)
because they expect operational synergies from integration.

2. Financial sponsors (KKR) pay lower premiums (12.4%) because they focus on
financial engineering and operational improvements rather than synergies.

3. Most deals have a synergy-to-premium ratio close to or above 1.0x, meaning
acquirers expect synergies to at least cover the premium paid.

4. The Cipla Health deal has the lowest ratio (0.60x) — Dr. Reddy's paid a premium
that exceeds expected synergies, possibly due to competitive bidding.
Strategic acquirers pay higher premiums; PE firms are more disciplined. Synergies generally justify premiums.

🏋️ Exercise 4 (Advanced): Football Field Valuation Range

Create a "football field" chart in Excel showing MedCore's valuation from different methodologies:

  1. Using the 25th and 75th percentile EV/EBITDA multiples from the precedent data, calculate a low and high implied share price
  2. Add the DCF range (assume ₹340 − ₹420 per share from a prior DCF analysis)
  3. Add the trading comps range (assume ₹310 − ₹380 from Session 12 methodology)
  4. Create a horizontal bar chart in Excel showing all ranges side by side

Hint: Use =PERCENTILE(range, 0.25) and =PERCENTILE(range, 0.75) in Excel.

1
Calculate Percentile Multiples
EV/EBITDA values: 11.8, 8.0, 9.0, 9.5, 9.7, 9.0, 9.8, 8.4, 8.2, 8.8

25th Percentile: =PERCENTILE(range, 0.25) = 8.55x
Median (50th): =PERCENTILE(range, 0.50) = 9.0x
75th Percentile: =PERCENTILE(range, 0.75) = 9.65x
2
Precedent Transaction Range
Low (25th %ile): EV = ₹920 × 8.55x = ₹7,866 Cr → Equity = ₹7,216 Cr → ₹360.80/share
High (75th %ile): EV = ₹920 × 9.65x = ₹8,878 Cr → Equity = ₹8,228 Cr → ₹411.40/share
3
Complete Football Field Summary
┌─────────────────────────────────────────────────────────┐
│ Methodology Low High Current ₹310 │
├─────────────────────────────────────────────────────────┤
│ DCF Valuation ₹340 ₹420 │
│ Trading Comps ₹310 ₹380 │
│ Precedent Transactions ₹361 ₹411 │
├─────────────────────────────────────────────────────────┤
│ Overlap Zone ₹361 ₹380 ← CONSENSUS │
└─────────────────────────────────────────────────────────┘

To create the chart in Excel:
1. List each methodology in rows with Low/High columns
2. Insert → Bar Chart → Stacked Bar
3. First series = Low value (transparent/no fill)
4. Second series = High − Low (colored bars)
5. Add a vertical line at MedCore's current price (₹310)
Consensus valuation range: ₹361-₹380/share. At ₹310, MedCore trades at a 16-22% discount to the consensus range — potential acquisition candidate.
Review

Key Terms — Click to Flip

Master the vocabulary of Precedent Transaction Analysis

Knowledge Check

Test Your Understanding

10 objective questions on Precedent Transactions Analysis

Summary

Key Takeaways

📝 What We Covered Today

  • Precedent Transactions use actual M&A deal prices (not market prices) to derive valuation multiples — they inherently include a control premium.
  • The 5-step process: Select universe → Source data → Calculate multiples → Analyze premiums → Apply to target.
  • EV/EBITDA is the gold standard transaction multiple for capital-intensive industries like pharma; always report median alongside mean.
  • Control premiums in India range 15-35%; strategic acquirers pay more than financial sponsors due to synergy expectations.
  • Deal structure (cash vs. stock) affects the effective premium — 100% cash offers tend to have lower premiums than stock-based deals.
  • Synergy-to-premium ratios should ideally be ≥ 1.0x — meaning expected synergies at least cover the premium paid.
  • A football field chart combines DCF, trading comps, and precedent transactions to present a valuation range to stakeholders.
📚 Next Session

Session 14: M&A Modeling – I
We move from valuing companies to modeling actual acquisitions. Topics include acquisition assumptions, purchase price allocation, goodwill calculation, and building combined (pro forma) financials. Read: Rosenbaum & Pearl, Ch. 6